Trinity Biotech plc
Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Asia, Africa, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; se… Read more
Trinity Biotech plc (TRIB) - Net Assets
Latest net assets as of September 2025: $-54.72 Million USD
Based on the latest financial reports, Trinity Biotech plc (TRIB) has net assets worth $-54.72 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($103.71 Million) and total liabilities ($158.43 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-54.72 Million |
| % of Total Assets | -52.76% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | -116.45% |
| Growth Volatility | 106.18 |
Trinity Biotech plc - Net Assets Trend (1993–2024)
This chart illustrates how Trinity Biotech plc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Trinity Biotech plc (1993–2024)
The table below shows the annual net assets of Trinity Biotech plc from 1993 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $-35.18 Million | -46.90% |
| 2023-12-31 | $-23.95 Million | -1000.60% |
| 2022-12-31 | $-2.18 Million | -582.13% |
| 2021-12-31 | $-319.00K | +85.62% |
| 2020-12-31 | $-2.22 Million | -147.08% |
| 2019-12-31 | $4.71 Million | -89.30% |
| 2018-12-31 | $44.05 Million | -32.43% |
| 2017-12-31 | $65.20 Million | -40.04% |
| 2016-12-31 | $108.73 Million | -49.17% |
| 2015-12-31 | $213.89 Million | +8.59% |
| 2014-12-31 | $196.97 Million | +7.63% |
| 2013-12-31 | $183.01 Million | +8.05% |
| 2012-12-31 | $169.38 Million | +11.93% |
| 2011-12-31 | $151.33 Million | +7.11% |
| 2010-12-31 | $141.29 Million | +78.07% |
| 2009-12-31 | $79.34 Million | +20.39% |
| 2008-12-31 | $65.91 Million | -51.84% |
| 2007-12-31 | $136.84 Million | -18.19% |
| 2006-12-31 | $167.26 Million | +25.18% |
| 2005-12-31 | $133.62 Million | +15.05% |
| 2004-12-31 | $116.14 Million | +44.70% |
| 2003-12-31 | $80.26 Million | +27.59% |
| 2002-12-31 | $62.91 Million | +11.28% |
| 2001-12-31 | $56.53 Million | +2.71% |
| 2000-12-31 | $55.04 Million | +142.25% |
| 1999-12-31 | $22.72 Million | +55.63% |
| 1998-12-31 | $14.60 Million | +105.63% |
| 1997-12-31 | $7.10 Million | -33.02% |
| 1996-12-31 | $10.60 Million | +41.33% |
| 1995-12-31 | $7.50 Million | +476.92% |
| 1994-12-31 | $1.30 Million | -58.06% |
| 1993-12-31 | $3.10 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Trinity Biotech plc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 7501700000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $4.19 Million | % |
| Other Comprehensive Income | $-5.44 Million | % |
| Other Components | $45.18 Million | % |
| Total Equity | $-35.18 Million | 100.00% |
Trinity Biotech plc Competitors by Market Cap
The table below lists competitors of Trinity Biotech plc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
BATT.OIL COR. B DL-0001
F:RAQB
|
$15.89 Million |
|
Marygold Companies Inc
NYSE MKT:MGLD
|
$15.90 Million |
|
Dexin Corporation
TWO:3349
|
$15.90 Million |
|
Lian Fa International Dining Business Corp.
TWO:2756
|
$15.90 Million |
|
Elevation Oncology Inc
NASDAQ:ELEV
|
$15.88 Million |
|
Telkom
JSE:TKG
|
$15.88 Million |
|
ASEC International Corporation
TWO:6113
|
$15.88 Million |
|
Nirvana Daii Public Company Limited
BK:NVD
|
$15.88 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Trinity Biotech plc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -23,949,000 to -35,181,000, a change of -11,232,000.
- Net loss of 31,789,000 reduced equity.
- New share issuances of 7,391,000 increased equity.
- Other comprehensive income decreased equity by 6,464,000.
- Other factors increased equity by 19,630,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-31.79 Million | -90.36% |
| Share Issuances | $7.39 Million | +21.01% |
| Other Comprehensive Income | $-6.46 Million | -18.37% |
| Other Changes | $19.63 Million | +55.8% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Trinity Biotech plc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1993-12-31 | $1.68 | $0.74 | x |
| 1994-12-31 | $0.52 | $0.74 | x |
| 1995-12-31 | $3.36 | $0.74 | x |
| 1996-12-31 | $4.75 | $0.74 | x |
| 1997-12-31 | $1.28 | $0.74 | x |
| 1998-12-31 | $6.55 | $0.74 | x |
| 1999-12-31 | $10.29 | $0.74 | x |
| 2000-12-31 | $22.15 | $0.74 | x |
| 2001-12-31 | $22.26 | $0.74 | x |
| 2002-12-31 | $24.54 | $0.74 | x |
| 2003-12-31 | $26.58 | $0.74 | x |
| 2004-12-31 | $29.27 | $0.74 | x |
| 2005-12-31 | $45.55 | $0.74 | x |
| 2006-12-31 | $51.06 | $0.74 | x |
| 2007-12-31 | $35.99 | $0.74 | x |
| 2008-12-31 | $16.19 | $0.74 | x |
| 2009-12-31 | $18.95 | $0.74 | x |
| 2010-12-31 | $33.35 | $0.74 | x |
| 2011-12-31 | $35.54 | $0.74 | x |
| 2012-12-31 | $7.55 | $0.74 | x |
| 2013-12-31 | $7.81 | $0.74 | x |
| 2014-12-31 | $8.30 | $0.74 | x |
| 2015-12-31 | $39.02 | $0.74 | x |
| 2016-12-31 | $19.21 | $0.74 | x |
| 2017-12-31 | $12.13 | $0.74 | x |
| 2018-12-31 | $8.51 | $0.74 | x |
| 2019-12-31 | $0.93 | $0.74 | x |
| 2020-12-31 | $-0.53 | $0.74 | x |
| 2021-12-31 | $-0.06 | $0.74 | x |
| 2022-12-31 | $-0.28 | $0.74 | x |
| 2023-12-31 | $-3.13 | $0.74 | x |
| 2024-12-31 | $-1.96 | $0.74 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Trinity Biotech plc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -51.64%
- • Asset Turnover: 0.60x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-18.68%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1993 | -141.67% | -141.67% | 0.49x | 2.04x | $-3.64 Million |
| 1994 | -253.85% | -63.46% | 1.68x | 2.38x | $-3.43 Million |
| 1995 | -10.67% | -8.08% | 1.08x | 1.23x | $-1.55 Million |
| 1996 | -8.49% | -12.50% | 0.54x | 1.26x | $-1.96 Million |
| 1997 | 16.90% | 7.14% | 0.68x | 3.46x | $490.00K |
| 1998 | 17.81% | 11.21% | 0.52x | 3.08x | $1.14 Million |
| 1999 | 21.42% | 18.83% | 0.58x | 1.96x | $2.62 Million |
| 2000 | 8.81% | 16.22% | 0.44x | 1.23x | $-649.81K |
| 2001 | 2.58% | 3.91% | 0.48x | 1.37x | $-4.17 Million |
| 2002 | 8.00% | 9.64% | 0.58x | 1.43x | $-1.25 Million |
| 2003 | 7.22% | 8.83% | 0.56x | 1.47x | $-2.23 Million |
| 2004 | 4.45% | 6.46% | 0.53x | 1.30x | $-6.45 Million |
| 2005 | 3.95% | 5.36% | 0.53x | 1.38x | $-8.08 Million |
| 2006 | 1.96% | 2.76% | 0.48x | 1.49x | $-13.45 Million |
| 2007 | -25.85% | -24.63% | 0.66x | 1.58x | $-49.06 Million |
| 2008 | -118.02% | -55.50% | 1.08x | 1.97x | $-84.37 Million |
| 2009 | 14.90% | 9.39% | 0.95x | 1.67x | $3.89 Million |
| 2010 | 42.76% | 67.40% | 0.56x | 1.14x | $46.29 Million |
| 2011 | 10.30% | 20.00% | 0.45x | 1.13x | $459.80K |
| 2012 | 10.24% | 21.02% | 0.42x | 1.17x | $403.00K |
| 2013 | 5.65% | 11.33% | 0.40x | 1.24x | $-7.96 Million |
| 2014 | 8.74% | 16.41% | 0.43x | 1.23x | $-2.48 Million |
| 2015 | 10.19% | 21.75% | 0.28x | 1.68x | $407.20K |
| 2016 | -92.55% | -101.02% | 0.40x | 2.30x | $-111.50 Million |
| 2017 | -61.77% | -40.62% | 0.51x | 2.95x | $-46.79 Million |
| 2018 | 5.43% | 2.46% | 0.64x | 3.43x | $-2.02 Million |
| 2019 | -86.27% | -4.50% | 0.69x | 27.81x | $-4.54 Million |
| 2020 | 0.00% | -6.26% | 0.78x | 0.00x | $-6.17 Million |
| 2021 | 0.00% | 1.08% | 0.68x | 0.00x | $906.90K |
| 2022 | 0.00% | -65.58% | 0.68x | 0.00x | $-40.78 Million |
| 2023 | 0.00% | -42.26% | 0.96x | 0.00x | $-21.62 Million |
| 2024 | 0.00% | -51.64% | 0.60x | 0.00x | $-28.27 Million |
Industry Comparison
This section compares Trinity Biotech plc's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $694,749,556
- Average return on equity (ROE) among peers: -25.46%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Trinity Biotech plc (TRIB) | $-54.72 Million | -141.67% | N/A | $15.89 Million |
| Advanced Biomedical Technologies Inc (ABMT) | $-4.46 Million | 0.00% | 0.00x | $14.18K |
| Abbott Laboratories (ABT) | $4.82 Billion | 39.04% | 1.31x | $191.37 Billion |
| Acarix AB (publ) (ACIXF) | $1.93 Million | -127.02% | 0.21x | $26.42 Million |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-72.62 Million | 0.00% | 0.00x | $4.05 Million |
| Adm Tronics Unltd (ADMT) | $-12.69K | 0.00% | 0.00x | $3.17 Million |
| Aethlon Medical Inc (AEMD) | $-3.07 Million | 0.00% | 0.00x | $2.79 Million |
| Acutus Medical Inc (AFIB) | $126.58 Million | -80.56% | 0.52x | $732.88K |
| Adapthealth Corp (AHCO) | $2.07 Billion | 7.56% | 1.54x | $914.25 Million |
| Allied Healthcare Products Inc. (AHPIQ) | $8.88 Million | -33.95% | 1.22x | $726.24 |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $3.39 Million | -59.65% | 0.38x | $9.18 Million |